Used in targeted cancer therapies, particularly for mesothelin-expressing tumors such as mesothelioma, non-small cell lung cancer, ovarian cancer, and pancreatic ductal adenocarcinoma. It functions as a monoclonal antibody that binds to mesothelin on the cell surface, enabling immune-mediated destruction of tumor cells through mechanisms like antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). It is also investigated in combination with other immunotherapies to enhance anti-tumor responses. Additionally, it serves as a reference standard in the development of mesothelin-targeted biologics and diagnostic agents.